Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

le.  NKTR-102 was invented by Nektar using its advanced polymer conjugate technology platform, and is the first oncology product candidate to leverage Nektar's releasable polymer technology platform.  

In addition to the fully-enrolled Phase 2 studies in platinum-refractory/resistant ovarian cancer and metastatic breast cancer, NKTR-102 is also being tested in a separate Phase 2 clinical trial in patients with second-line colorectal cancer and a Phase 1 clinical trial evaluating NKTR-102 in combination with 5-FU therapy.  An expansion arm of the Phase 2 study of single-agent NKTR-102 in platinum-refractory/resistant ovarian cancer in women who failed prior Doxil therapy is also currently enrolling.  A Phase 3 study of single-agent NKTR-102 is planned in metastatic breast cancer.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms.  Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules.  In addition to the releasable polymer technology, Nektar is the first company to create a permanent small molecule-polymer conjugate with enhanced oral bioavailability and restricted entry into the CNS.  Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas.  Nektar has an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 pr
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014 CTI BioPharma ... it will report its second quarter 2014 financial results ... the U.S. financial markets. Following the announcement, members of ... to discuss the results and provide a general corporate ... to the event can be obtained as follows: ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems Market Outlook ... Capsule Endoscopy Systems market. The report provides value, in ... prices (in US dollars) within market segments: ... Capsule Endoscopes , Capsule Endoscopy Data Recorders ... also provides company shares and distribution shares data for ...
(Date:7/25/2014)... 25, 2014  CVS Caremark Corporation (NYSE: ... Tuesday, August 5, 2014, at 8:30 a.m. (EDT) with ... financial results. An audio webcast of the ... Relations portion of the CVS Caremark website for all ... . This webcast will be archived and available on ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2014 Financial Results on August 4, 2014 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5
... 07, 2007 /PRNewswire-FirstCall/ --,Mymetics Corporation announced today ... vaccine elicited neutralizing,IgA mucosal antibodies in a ... as a possible first line of defense,against ... by Sylvain,Fleury, Ph.D., Mymetics' Chief Scientific Officer, ...
... 7, 2007 - Dynogen,Pharmaceuticals, Inc. reported positive ... trial of DDP733 for,gastroesophageal reflux disease (GERD). ... DDP733 as a treatment for,nocturnal GERD (NGERD). ... significance over placebo on the primary endpoint ...
Cached Medicine Technology:Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 2Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 3Mymetics' HIV Vaccine Demonstrates First-Ever Production of,Neutralizing IgA Antibodies in Non-Human Primate Model 4Dynogen Reports Positive Results in Phase 1B GERD Study 2Dynogen Reports Positive Results in Phase 1B GERD Study 3Dynogen Reports Positive Results in Phase 1B GERD Study 4
(Date:7/28/2014)... July 28, 2014 A St. Jude ... adult survivors of childhood cancer more than doubled their ... by failing to follow a heart-healthy lifestyle. The results ... , Almost 32 percent of the 1,598 adult survivors ... an umbrella term for health risk factors like high ...
(Date:7/28/2014)... July 2014: ESC Congress 2014 promises to be bigger, ... Keith Fox, Chair of the Congress Programme Committee. The ... most influential cardiovascular event every year in August. Record ... this year and the congress is on track to ... , Asked why an extra hot line session ...
(Date:7/28/2014)... group of researchers in Taiwan has developed a new ... early complication of diabetes sooner, when it is more ... in clinical trials, it may pave the way for ... complication, called diabetic autonomic neuropathy, which is common among ... The condition progressively affects the autonomic nerves controlling vital ...
(Date:7/28/2014)... Brea, CA (PRWEB) July 28, 2014 ... management business process outsourcing (BPO) for Fortune 500 brands, ... 2,500 jobs across its locations in Wisconsin, California, Florida ... will be based at its Brea campus. , A ... clients, which have seasonal ramp-ups that require additional staffing ...
(Date:7/28/2014)... Brisbane, Australia (PRWEB) July 28, 2014 ... achieve a happier lifestyle can often be a struggle ... international channel, psychic and medium, Lynette Leckie-Clark provides simple ... new book “The Magic of You.” With inspiring spiritual ... thinking, you can find empowerment, confidence and motivation for ...
Breaking Medicine News(10 mins):Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 2Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 3Health News:Unhealthy Habits More than Double Risk of Metabolic Syndrome in Childhood Cancer Survivors 4Health News:ESC Congress 2014 focuses on innovations in cardiology 2Health News:ESC Congress 2014 focuses on innovations in cardiology 3Health News:Wearable device for the early detection of common diabetes-related neurological condition 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 2Health News:Alta Resources to Fill Approximately 700 Positions in Brea 3Health News:Be Empowered to Achieve Happiness from New Book "The Magic of You" 2
... being fed contaminated feed is causing concern among the people. The ... years . The FDA is quick to play down the fear ... ,This concern came to light after some 38 chicken farms in ... farms fed the chicken for human consumption with the contaminated feed. ...
... C (HCV), survival has improved over time. However, for ... to a study in the issue of Liver Transplantation. ... reason for liver transplantation in the U.S., however, previous ... as well to liver transplantation. The difference has become ...
... governor, James E. McGreevy appears to be knocking on a ... the news for the right reasons. He has been ... ,Former Gov. James E. McGreevy, who was brought up as ... on Sunday at St. Bartholomew's Church in New York. He ...
... said the government is working to draft a law allowing ... of genetic disorders. ,"We are studying it from ... choice to have the abortion will be under the umbrella ... religious and social environment," Ali Shakar of the ministry of ...
... more than twice as likely to also have symptoms of ... not have migraines, according to research. ,The study involved ... screening questionnaire within 90 days after returning from one year ... the soldiers, or 60 percent, completed the questionnaire. Of those, ...
... warming, but only few act. ,The ... has two parts. One, human beings get stubbornly comfortable in ... programmed to act in its own best interests - and ... point. ,In addition, the overwhelming size and abstract ...
Cached Medicine News:Health News:Tainted Pet Food a Health Risk for Human? 2Health News:HCV Patients Survival After Liver Transplantation is Not Improving 2Health News:Migraines may Be a Symptom of Other Problems for Iraq Soldiers 2Health News:Why Humans Fail to Act on Climate Change 2Health News:Why Humans Fail to Act on Climate Change 3
... operating and recovery room, ,The Cardiocap ... haemodynamic and airway gas monitoring for induction ... units. The Cardiocap II is available in ... haemodynamic measurements. Two of the models include ...
Precordial Chestpieces are manufactured from chrome plated brass. Provides a hollow design with deep sound chambers for optimum acoustics....
For accurately monitoring heart and breath sounds....
For accurately monitoring core temperature and heart and breath sounds....
Medicine Products: